Nature Biotechnology, November 2009 by Sarah Webb
http://www.nature.com/nbt/journal/v27/n11/full/nbt1109-977.html
“You have the tension that this just looks like a really attractive technology to commercialize. Then you have the challenge that we’re not clear on what we can patent or what we can’t patent,” says Ken Taymor, executive director of the Berkeley Center for Law, Business and the Economy in California.
